Skip to main content

Harding Thomas C.'s Form 4 filing

Clovis Oncology, Inc. (CLVS) · filed Jun 3, 2022

Accession no.
0000899243-22-020948
Filed
Jun 3, 2022
Trade date
Jun 1-2, 2022
Filing delay
2 days
Rule 10b5-1 plan
Not on the form (before 2023)

This filing lists 4 non-derivative transactions and 2 derivative transactions. Open-market sales total $1.10K. It was filed 2 days after the trade.

Reporting owners

A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.

Reporting owners on this filing
OwnerRelationship to the company
Harding Thomas C.CIK 0001834833Officer (See Remarks)

Non-derivative securities (Table I)

Acquisitions and disposals of common stock and similar shares, one row per line on the filing.

Non-derivative transactions
Trade dateSecurityTransactionSharesPriceValueShares afterOwnershipFlags
Jun 1, 2022Common StockMOption exerciseAcquired+2,896–F1–16,224Direct
Jun 2, 2022Common StockSSaleDisposed−1,504$0.64F3−$962.5614,720Direct
Jun 1, 2022Common StockMOption exerciseAcquired+507–F1–3,443Indirect
Jun 2, 2022Common StockSSaleDisposed−218$0.64F4−$139.523,225Indirect

Derivative securities (Table II)

Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.

Derivative transactions
Trade dateSecurityTransactionUnderlying sharesUnit priceValueHeld afterOwnershipFlags
Jun 1, 2022Common StockMOption exerciseAcquired+2,896$0.00$031,854Direct
Jun 1, 2022Common StockMOption exerciseAcquired+507$0.00$03,555Indirect

Footnotes and remarks

Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.

F1

Each Restricted Stock Unit represents the right to receive one share of Common Stock.

Referenced by the price of 2 transactions in Table I.

F3

This transaction was executed in multiple trades at prices ranging from $0.642368 to $0.645200. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

Referenced by the price of 1 transaction in Table I.

F4

This transaction was executed in multiple trades at prices ranging from $0.642300 to $0.642368. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

Referenced by the price of 1 transaction in Table I.

Remarks

Executive Vice President and Chief Scientific Officer

Read the full filing on SEC EDGAR (opens in a new tab)